Scholar Rock Holding (SRRK) Operating Expenses (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Operating Expenses of $102.0 million for Q1 2026, up 32.33% year-over-year from $77.1 million in Q1 2025, and up 11.01% quarter-over-quarter from $91.9 million in Q4 2025.
Scholar Rock Holding (SRRK) Operating Expenses (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Operating Expenses history runs 10 years deep, the most recent figure standing at $102.0 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 32.33% year-over-year to $102.0 million; the TTM figure through Mar 2026 stood at $409.6 million (up 51.29% YoY), while the FY2025 annual figure was $384.6 million, up 52.6% from the prior year.
- Operating Expenses for Q1 2026 stood at $102.0 million, up from $91.9 million in the prior quarter.
- The five-year high for Operating Expenses was $112.1 million in Q2 2025, with the low at $39.1 million in Q2 2023.
- The 5-year median for Operating Expenses is $58.4 million (2024), against an average of $63.4 million.
- The sharpest annual moves came in 2023 and 2025: Operating Expenses slipped 9.42% in 2023, then jumped 88.42% in 2025.
- Scholar Rock Holding's Operating Expenses stood at $40.4 million in 2022, then gained by 18.81% to $48.0 million in 2023, then jumped by 44.4% to $69.4 million in 2024, then jumped by 32.5% to $91.9 million in 2025, then advanced by 11.01% to $102.0 million in 2026.
- Business Quant data shows SRRK's Operating Expenses at $102.0 million in Q1 2026, $91.9 million in Q4 2025, and $103.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - | 108.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 108.90 Mn |
| Mar 31, 2026 | 102.02 Mn |
| Dec 31, 2025 | 91.90 Mn |
| Sep 30, 2025 | 103.55 Mn |
| Jun 30, 2025 | 112.11 Mn |
| Mar 31, 2025 | 77.09 Mn |
| Dec 31, 2024 | 69.36 Mn |
| Sep 30, 2024 | 64.78 Mn |
| Jun 30, 2024 | 59.50 Mn |
| Mar 31, 2024 | 58.42 Mn |
| Dec 31, 2023 | 48.03 Mn |
| Sep 30, 2023 | 43.67 Mn |
| Jun 30, 2023 | 39.08 Mn |
| Mar 31, 2023 | 40.51 Mn |
| Dec 31, 2022 | 40.43 Mn |
| Sep 30, 2022 | 43.86 Mn |
| Jun 30, 2022 | 43.15 Mn |
| Mar 31, 2022 | 40.13 Mn |
| Dec 31, 2021 | 39.41 Mn |
| Sep 30, 2021 | 42.54 Mn |